Nanobiotechnology and Nanomedicine Companies
Showing results 1 - 20 of 40 for suppliers of Delivery:
Develops Nanobodies, antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally-occurring heavy-chain antibodies.
Aposense is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents based on the identification and targeting of cells undergoing apoptosis (programmed cell death).
Develops and manufactures micelle-like nanoparticulate encapsulation technology for applications in food, cosmetics, pharmaceuticals and biotechnology.
Designs, engineers and fabricates coatings, capsules, and "Artificial Cells" from polymers called polypeptides by a method called layer-by-layer self-assembly (LBL).
A biotechnology company engaged in the development and delivery of novel protein and cellular based therapies through design of proprietary Biological Nano Particles.
Develops nanotechnology drug delivery systems based on novel nanomaterials that provide precise control over location and timing of drug delivery.
Camurus specializes in the development of pharmaceuticals based on advanced and effective innovative nanoscale drug delivery systems that optimize the bioavailability and therapeutic performance of a wide range of difficult substances, including: peptides, proteins, and insoluble small molecules.
Commercializes a nano and micron sized ceramic spheres technology that provides encapsulation and controlled release of active molecules for a variety of applications including drug delivery, cosmeceuticals and speciality chemicals.
The company focuses on the production of novel active pharmaceutical ingredients and nanomedicines.
The group is involved in the rapidly developing field of nanobiopharmacy. It focuses on tissue engineering (e.g. scaffolds for cartilage and skin replacement, differentiation of stem cells into chondrocytes), wound healing, gene therapy and targeted drug delivery (using above mentioned polysaccharides and their conjugates). The research and innovation is an integral part of the company activities. Due to recent investments in the state-of-the art laboratory equipment and experienced and motivated scientists the company creates a unique center for regenerative medicine research, including various in-vitro and in-vivo tests.
Developed a technology to compact DNA into complexes containing only a single molecule of DNA, resulting in a volume 30-1000 times smaller than other complexes. This simple difference makes Copernicus' "DNA nanoparticles" highly stable and uniquely able to deliver DNA to the nuclei of non-dividing human cells - which includes most cells in the body.
The Company is developing a pipeline of multifunctional, next-generation therapeutics, binding known anti-cancer agents to its patented colloidal gold tumor-targeting nanotechnology.
Applies nanotechnology to the design and manufacture of pumps, coatings and micro-needle arrays.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company also has developed a microfabricated nanopore device for the sustained release of therapeutic agents.
The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
The company is developing therapeutic immunotherapy by incorporating virus-specific immunogenic DNA into nanoparticles.
The company's focus is on the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases. Their technologies also hold the promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention.
The foundation of the company's IVEC™ drug delivery platform is based on polymer micelle technology, spherical nanosized capsules formed by the assembly of block copolymers in water.
Keystone Nano has an exclusive license to Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles that they call Molecular Dots (MDs). These Molecular Dots can encapsulate drugs and/or fluorescent molecules.
The combination of a protected blood transporting nanocarrier system and a tumor specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive and dynamic anticancer market, where drug delivery systems will gain increasing importance over the coming years.